Research programme: antibody drug conjugates - Merck KGaA/Sutro Biopharma
Latest Information Update: 19 Sep 2014
At a glance
- Originator Merck KGaA; Sutro Biopharma
- Developer Sutro Biopharma
- Class Drug conjugates; Immunoconjugates
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Research Cancer
Most Recent Events
- 17 Sep 2014 Early research in Cancer in USA (unspecified route)